To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
13 August 2021
In July 2021, Initiator Pharma A/S (“Initiator Pharma”) conducted a rights issue in which the general public was given the opportunity to subscribe. Through the rights issue, a total of 7,958,628 shares were issued. The rights issue has now been registered at the Danish Business Authority and the last day of trading in BTA (paid for shares) is on the 18[th] of August 2021. The stop date will be on the 20[th] of August 2021.
On July 26, 2021, the subscription period in Initiator Pharma A/S (“Initiator Pharma” or “the Company”) rights issue of shares ended. The rights issue was subscribed for to a total of approximately 227 percent by existing shareholders, the public and through pre-subscription commitments. Thus, none of the underwriting commitments had to be activated. The Company is provided the total issue volume of approximately SEK 29.4 million before issue costs. Settlement notes are scheduled to be sent out today, 29 July 2021.
Today, 12 July 2021, the subscription period begins in Initiator Pharma A/S (“Initiator Pharma” or “the Company”) rights issue of shares in which the public is also given the opportunity to subscribe. The subscription period runs until and including 26 July 2021. A fully subscribed rights issue provides the Company with a maximum of approximately SEK 29.4 million before issue costs. Prior to the rights issue, Initiator Pharma has through written agreements agreed on subscription commitments and underwriting commitments corresponding to a total of 100 percent of the issue amount.
Initiator Pharma A/S (“Initiator Pharma” or “the Company”) today announces that Finanstilsynet has approved the Company’s prospectus for the forthcoming preferential rights issue and that the Company today publishes the prospectus on the Company’s website. The prospectus can be found through the following link https://initiatorpharma.com/investors/Preferential-Rights-Issue-2021/. The subscription period for the preferential rights issue will take place between 12 July and 26 July 2021. Teaser and subscription forms will be published in connection with the start of the subscription period.
The Board of Directors of Initiator Pharma A/S decides on execution of previously communicated preferential rights issue
The Board of Directors of Initiator Pharma A / S (“Initiator Pharma” or “the Company”) has today decided on execution of a preferential rights issue (which has previously been communicated) with the support of authorization from the Extraordinary General Meeting on May 11, 2021. The terms and preliminary schedule for the issue, which has previously been determined and communicated through a press release, are presented below. It is noted that the Board of Directors has the right to postpone the subscription period in the issue, in the event that Finanstilsynet does not approve the Company’s prospectus in time. In the event of a schedule adjustment, this will be communicated to the market through a press release.
Initiator Pharma receives CTA approval for Phase 2b study with IPED2015 in Erectile Dysfunction patients
Initiator Pharma A/S, a clinical-stage life science company, announced today that it has received final approvals for the Clinical Trial Application (CTA) for its planned Phase 2b study in Erectile Dysfunction patients with IPED2015 from both the Medicines & Healthcare products Regulatory Agency, MHRA, UK and the Ethics Committee. The patient recruitment is expected to start at end of July. The study will be carried out in collaboration with MAC Clinical Research, UK, at multiple centers across UK.
As previously communicated, Initiator Pharma A/S (“Initiator Pharma” or “the Company”) intends to carry out a preferential rights issue of a total of approximately SEK 29.4 million (before issue costs), which has been agreed in advance in writing through subscription and guarantee commitments to 100 percent. The Company’s prospectus is for review by Finanstilsynet Danmark and the Company hereby communicates an estimated time plan for the implementation of the preferential rights issue. The terms of the issue, which have previously been decided and communicated through a press release, are also set out below.